Ventricular ErbB2/ErbB4 activation and downstream signaling in pacing-induced heart failure

Journal of Molecular and Cellular Cardiology

Volumn 46, Issue 1, 2009, Pages 33-38

  Doggen, Kris ^a   Ray, Lynn ^b   Mathieu, Myrielle ^b   Mc Entee, Kathleen ^b   Lemmens, Katrien ^a   De Keulenaer, Gilles W ^a  

^a UNIVERSITY OF ANTWERP   (Belgium)

^b FREE UNIVERSITY OF BRUSSELS   (Belgium)

Author keywords

Akt; Endothelium; ErbB receptors; Heart failure; Neuregulin 1

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 4; MELTRIN BETA; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; NEU DIFFERENTIATION FACTOR; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN DERIVATIVE; PROTEIN KINASE B; TYROSINE; UNCLASSIFIED DRUG;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; DEVELOPMENT; DOG; ECHOCARDIOGRAPHY; HEART; HEART FAILURE; HEART MUSCLE BIOPSY; HEART PACING; HEART PROTECTION; HEART VENTRICLE; HEART VENTRICLE FUNCTION; IMMUNOPRECIPITATION; MALE; NONHUMAN; PATHOPHYSIOLOGY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN SECRETION; QUANTITATIVE ANALYSIS; RAT; WESTERN BLOTTING;

ANIMALS; APOPTOSIS; CARDIAC PACING, ARTIFICIAL; DOGS; ENDOTHELIUM; HEART FAILURE; HEART VENTRICLES; MALE; PEPTIDE HYDROLASES; PHOSPHORYLATION; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; RECEPTORS, LYSOSPHINGOLIPID; SIGNAL TRANSDUCTION;

CANIS FAMILIARIS;

EID: 57149098209     PISSN: 00222828     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.yjmcc.2008.10.010     Document Type: Article

References (29)

1. Lemmens K., Doggen K., and De Keulenaer G.W. Role of neuregulin-1/ErbB signaling in cardiovascular physiology and disease: implications for therapy of heart failure. Circulation 116 (2007) 954-960
2. Lemmens K., Segers V.F.M., Demolder M., and De Keulenaer G.W. Role of neuregulin-1/ErbB2 signaling in endothelium-cardiomyocyte cross-talk. J Biol Chem 281 (2006) 19469-19477
3. Lemmens K., Fransen P., Sys S.U., Brutsaert D.L., and De Keulenaer G.W. Neuregulin-1 induces a negative inotropic effect in cardiac muscle: role of nitric oxide synthase. Circulation 109 (2004) 324-326
4. Crone S.A., et al. ErbB2 is essential in the prevention of dilated cardiomyopathy. Nat Med 8 (2002) 459-465
5. Liu F., et al. Heterozygous knockout of neuregulin-1 gene in mice exacerbates doxorubicin-induced heart failure. Am J Physiol Heart Circ Physiol 289 (2005) H660-666
6. Liu X., et al. Neuregulin-1/erbB-activation improves cardiac function and survival in models of ischemic, dilated, and viral cardiomyopathy. J Am Coll Cardiol 48 (2006) 1438-1447
7. Brutsaert D.L. Cardiac endothelial-myocardial signaling: its role in cardiac growth, contractile performance, and rhythmicity. Physiol Rev 83 (2003) 59-115
8. Gabrielson K., Bedja D., Pin S., Tsao A., Gama L., Yuan B., and Muratore N. Heat shock protein 90 and ErbB2 in the cardiac response to doxorubicin injury. Cancer Res 67 (2007) 1436-1441
9. de Korte M.A., et al. 111Indium-trastuzumab visualises myocardial human epidermal growth factor receptor 2 expression shortly after anthracycline treatment but not during heart failure: a clue to uncover the mechanisms of trastuzumab-related cardiotoxicity. Eur J Cancer 43 (2007) 2046-2051
10. Seidman A., et al. Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol 20 (2002) 1215-1221
11. Rohrbach S., et al. Neuregulin in cardiac hypertrophy in rats with aortic stenosis. Differential expression of erbB2 and erbB4 receptors. Circulation 100 (1999) 407-412
12. Rohrbach S., Niemann B., Silber R., and Holtz J. Neuregulin receptors erbB2 and erbB4 in failing human myocardium - depressed expression and attenuated activation. Basic Res Cardiol 100 (2005) 240-249
13. Perik P.J., et al. Serum HER2 levels are increased in patients with chronic heart failure. Eur J Heart Fail 9 (2007) 173-177
14. Ray L., et al. Early increase in pulmonary vascular reactivity with overexpression of endothelin-1 and vascular endothelial growth factor in canine experimental heart failure. Exp Physiol 93 (2008) 434-442
15. Akiyama T., Matsuda S., Namba Y., Saito T., Toyoshima K., and Yamamoto T. The transforming potential of the c-erbB-2 protein is regulated by its autophosphorylation at the carboxyl-terminal domain. Mol Cell Biol 11 (1991) 833-842
16. Schulze W.X., Deng L., and Mann M. Phosphotyrosine interactome of the ErbB-receptor kinase family. Mol Syst Biol 1 (2005) 2005.0008
17. Zhang H.T., et al. Absence of autophosphorylation site Y882 in the p185neu oncogene product correlates with a reduction of transforming potential. Oncogene 16 (1998) 2835-2842
18. Ananthakrishnan R., Moe G.W., Goldenthal M.J., and Marín-García J. Akt signaling pathway in pacing-induced heart failure. Mol Cell Biochem 268 (2005) 103-110
19. Hanna N., Cardin S., Leung T., and Nattel S. Differences in atrial versus ventricular remodeling in dogs with ventricular tachypacing-induced congestive heart failure. Cardiovasc Res 63 (2004) 236-244
20. Chung K.Y., and Walker J.W. Interaction and inhibitory cross-talk between endothelin and ErbB receptors in the adult heart. Mol Pharmacol 71 (2007) 1494-1502
21. Motte S., et al. Early activation of cardiac and renal endothelin systems in experimental heart failure. Am J Physiol Heart Circ Physiol 285 (2003) H2482-2491
22. Matsui T., and Rosenzweig A. Convergent signal transduction pathways controlling cardiomyocyte survival and function: the role of PI 3-kinase and Akt. Journal of Molecular and Cellular Cardiology 38 (2005) 63-71
23. Roux P.P., and Blenis J. ERK and p38 MAPK-activated protein kinases: a family of protein kinases with diverse biological functions. Microbiol Mol Biol Rev 68 (2004) 320-344
24. Rohrbach S., Muller-Werdan U., Werdan K., Koch S., Gellerich N.F., and Holtz J. Apoptosis-modulating interaction of the neuregulin/erbB pathway with antracyclines in regulating Bcl-xS and Bcl-xL in cardiomyocytes. Journal of Molecular and Cellular Cardiology 38 (2005) 485-493
25. Ozcelik C., et al. Conditional mutation of the ErbB2 (HER2) receptor in cardiomyocytes leads to dilated cardiomyopathy. Proc Natl Acad Sci U S A 99 (2002) 8880-8885
26. Garcia-Rivello H., et al. Dilated cardiomyopathy in Erb-b4-deficient ventricular muscle. Am J Physiol Heart Circ Physiol 289 (2005) H1153-1160
27. Kuramochi Y., Guo X., and Sawyer D.B. Neuregulin activates erbB2-dependent src/FAK signaling and cytoskeletal remodeling in isolated adult rat cardiac myocytes. Journal of Molecular and Cellular Cardiology 41 (2006) 228-235
28. Molina M.A., Codony-Servat J., Albanell J., Rojo F., Arribas J., and Baselga J. Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells. Cancer Res 61 (2001) 4744-4749
29. Baselga J. Is circulating HER-2 more than just a tumor marker?. Clin Cancer Res 7 (2001) 2605-2607